---
title: "Kyowa Kirin secures FDA approval for Crysvita dosing update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286546805.md"
description: "Kyowa Kirin has received FDA approval for an updated dosing regimen of Crysvita, a treatment for X-linked hypophosphatemia (XLH). The new guidelines allow healthcare providers to increase the dose and frequency for patients with low serum phosphorus levels. Crysvita, a monoclonal antibody, targets FGF23 to improve phosphorus retention and vitamin D levels. This update aims to provide a more personalized treatment approach for XLH patients, enhancing their care options."
datetime: "2026-05-15T08:42:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286546805.md)
  - [en](https://longbridge.com/en/news/286546805.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286546805.md)
generator: "portal-rs"
---

# Kyowa Kirin secures FDA approval for Crysvita dosing update

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [4151.JP](https://longbridge.com/en/quote/4151.JP.md)

## Related News & Research

- [How Cognizant’s AI-Powered Benchling Deployment at Kyowa Kirin (CTSH) Has Changed Its Investment Story](https://longbridge.com/en/news/296072336.md)
- [Kura Oncology posts corporate presentation on KOMZIFTI launch, ziftomenib pipeline strategy](https://longbridge.com/en/news/295714112.md)
- [Inhibitor Therapeutics announces annual shareholder meeting](https://longbridge.com/en/news/296102203.md)
- [QcX Gold Announces Shareholder Approval for Arrangement | QCXGF Stock News](https://longbridge.com/en/news/296346174.md)
- [Observe Medical says UnoMeter Safeti Max clinical study accepted for publication in Infection Prevention in Practice](https://longbridge.com/en/news/296495418.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**